|Videos|January 10, 2022

Expert Discusses How DMT Differs From Other Psychedelic Medicines

Carol Routledge, PhD, chief medical and scientific officer at Small Pharma, discusses DMT, how it differs from other psychedelic medicines, and what the future holds for DMT-assisted treatments.

Carol Routledge, PhD, chief medical and scientific officer at Small Pharma, discussed DMT, how it differs from other psychedelic medicines, and what the future holds for DMT-assisted treatments.

She spoke about the benefits of DMT, what the treatment targets are, and early research of the drug.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME

Virtual Event

Breast Cancer Day of Education 2026

Tuesday, July 14, 2026

Virtual Event

Neuropsychiatry Day of Education 2026

Thursday, July 16, 2026

Expert Discusses How DMT Differs From Other Psychedelic Medicines

Related Content

GLP-1 RAs Linked to Lower Mortality, Amputation Risk in Patients With PAD and Type 2 Diabetes

The Weekly Dose: Rising Cyclosporiasis Cases, Psychedelic Therapy Safety Monitoring, and New FDA Approvals

How Pharmacy's Newest Board Certification Pioneers Pain and Palliative Care

AI Prescription Refills Spark Debate Over Safety, Oversight, and the Future of Clinical Care

Minoritized, Low-Income Families May Be Disproportionately Affected By MMRV Vaccine Withdrawal

Latest CME

Breast Cancer Day of Education 2026

Neuropsychiatry Day of Education 2026

Bridging Knowledge Gaps in HR+/HER2– Early-Stage Breast Cancer

From Flares to Freedom: Navigating the Journey of Patients With Chronic Spontaneous Urticaria With Next-Generation Therapies

NEIAP Conference 2026

Optimizing Lipid Management in Statin-Intolerant Populations: Payer Strategies for Evidence-Based Access and Risk Reduction

Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

Bridging Innovation and Access in HR-Positive/HER2-Negative Metastatic Breast Cancer: Implications for Managed Care

Addressing Gaps in Care for the Rapid and Long-Term Management of Hyperkalemia With Novel Oral Potassium Binding Agents: Insights for Managed Care Professionals

Advancing Treatment Strategies in Extensive-Stage Small Cell Lung Cancer: Enhancing Pharmacist Competence in Therapy Selection, Administration, and Adverse Event Management

From Payload to Patient: Managing Toxicities of Antibody-Drug Conjugates Directed at HER2 and TROP2

Managing Steroid-Refractory Chronic Graft-versus-Host Disease With Novel Therapies: Opportunities for Pharmacist-Led Interventions

Artificial Intelligence in Pharmacy Practice: Validated Tools, Real-World Applications, and Emerging Innovations (Pharmacy Technician Credit)

Continuing the Conversation: Pharmacist Interventions to Optimize T2D Care and Break Through Clinical Inertia

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape

Expanding the Role of Long-Acting Injectables in Optimizing Schizophrenia Management

Neuropsychiatry Day of Education 2026

VMAT2 Inhibitors for Long-Term Success in Tardive Dyskinesia

Lymphoma Day of Education 2026

Breast Cancer Day of Education 2026

Adapting to Advances in EGFR-Positive Non-Small Cell Lung Cancer Treatment: Critical Insights for Oncology Pharmacists

Securing the Supply Chain: The Pharmacists’ Role in DSCSA Compliance

Navigating Adverse Effects in HR+/HER2-Negative Metastatic Breast Cancer: Tailored Management Plans and Pharmacist Interventions for Improved Outcomes

Breaking Barriers in Asthma Care: Exploring the Role of Type 2 Inflammation and Biologic Therapies

Advancing Pharmacist Expertise in R/R FL: Navigating Novel Therapies and Optimizing Patient Outcomes

From Molecules to Medicine: Pharmacologic Principles of Innovative Non-Hodgkin Lymphoma Therapies

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians

Biomarker Testing in Practice: Navigating Modalities and Multidisciplinary Decision-Making

Exploring Oncolytic Viruses in Melanoma: Pharmacist-Led Approaches for Safe Integration

Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Lymphomas: A Practical Guide for Pharmacists

Targeting the Complement Cascade: Evolving Strategies in the Management of Complement-Mediated Kidney Diseases

Optimizing HER2-Directed Therapy in Metastatic Breast Cancer: From HER2-Positive to HER2-Ultralow

Chronic Obstructive Pulmonary Disease and Inflammation: Practical Approaches to Integrating Biologic Therapy

Understanding Type 2 Inflammation and Its Role Across Various Immune-Related Diseases

Outsmart the Algorithm: Combatting Misinformation at the Pharmacy Counter

Shifting Perspectives in Treatment-Resistant Depression: Novel Therapies and Patient-Centered Care

Optimizing Therapy in HR+/HER2-Negative Metastatic Breast Cancer: Navigating Novel Treatments and Personalized Care

Translating KDIGO Updates and Clinical Evidence Into Managed Care Decision-Making in IgA Nephropathy

Shaping the Future of Generalized Myasthenia Gravis Management: A Focus on Novel Treatment Approaches

Type 2 Inflammation in Focus: Advancing Pediatric Atopic Dermatitis Care With Biologic Therapies

Expert Insights on the Horizon of HER2-Directed Therapy

Innovations in Lymphoma Treatment and the Growing Impact of Bispecific Antibodies

Addressing the Burden of Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: The Pharmacist's Contribution to Patient Care

Updated Guidance and Managed Care Strategies to Optimize Care in EGFR Mutated NSCLC

Payment for Pharmacist Services: 2025 Update

From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape

The Oncology Pharmacist's Role in Managing Small Molecule Inhibitor Use in Chronic Lymphocytic Leukemia to Enhance Patient-Centered Care

Lymphoma Day of Education 2026

Redefining Complement-Mediated Kidney Disease: The Latest in Diagnosis and Treatment

The Educated Pharmacist - Weighing In: Translating Evidence to Practice — A Multidisciplinary Analysis of Obesity Pharmacotherapy Implementation and Team-Based Care

Paroxysmal Nocturnal Hemoglobinuria: Managed Care Strategies to Mitigate Burden and Enhance Outcomes

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists

Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions

Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Optimizing Patient Outcomes in R/R DLBCL: Bridging Knowledge Gaps for Oncology Pharmacists in the Era of Novel Immunotherapies

Clinical Panel Debate: CAR T-Cell Therapy vs Bispecific Antibodies

The Pharmacist's Role in Palliative and End of Life Symptom Management (Pharmacy Technician Credit)

The Pharmacist's Role in Palliative and End of Life Symptom Management

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients (Pharmacy Technician Credit)

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients

Precision Matters: Foundations of Biomarker-Driven Care in Non-Small Cell Lung Cancer

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians (Pharmacy Technician Credit)

From Testing to Treatment: Empowering Pharmacists to Overcome Barriers and Optimize Biomarker-Driven Care

Clinical Presentation of Hyperglycemia with PI3K and AKT Inhibitors

Reducing the Treatment Burden in HIV Management: The Pharmacist’s Role in Long-Acting Injectable Adoption

Addressing Vaccine Hesitancy in Infectious Disease Prevention

Protecting Against Meningococcal Disease: Updates on Vaccines, Guidelines, and Pharmacist Best Practices

IL-23 Inhibitors in Psoriasis: Optimizing Access and Patient Outcomes Across Integrated Systems

Utilizing VMAT-2 Inhibitors for the Management of Tardive Dyskinesia: The Role of Long-Term Care Pharmacists

The Expanding Therapeutic Landscape in IgA Nephropathy: Translating New Clinical Evidence and Updated Guidelines Into Managed Care Strategies

The Expanding Therapeutic Landscape in IgA Nephropathy: A Case-Based Exploration of Optimized Patient Outcomes